Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3820MR)

This product GTTS-WQ3820MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3820MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4684MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ1463MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ2344MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ6811MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ13108MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ6651MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ5098MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ12536MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW